Dirk De Ruysscher - Concepedia

Author

Dirk De Ruysscher

Also Known As

D De Ruysscher, D de Ruysscher, D. De Ruysscher, D. de Ruysscher, D.De Ruysscher, Dirk De Ruysscher, Dirk de Ruysscher, Reymen, Bart, Ruysscher, Dirk De, Walter Weder

536

Publications

15.5K

Citations

H-Index

Concepts

All Affiliations

Maastro Clinic Maastricht University Medical Centre KU Leuven Maastricht University University Hospital of Zurich

About

Dirk De Ruysscher is an author at Maastro Clinic specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	63	6.5K
2	Health Sciences	30	44	5.1K
3	Engineering	4	4	234
4	Public Health	1	1	32
5	Biochemistry	1	1	17

Dirk De Ruysscher

106

Publications

8.9K

Citations

H-Index

Page 1

	Year	Citations
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Martin Reck, Sanjay Popat, Niels Reinmuth, Annals of Oncology Advanced Lung DiseaseMedicineCancer ManagementOncologyRadiation Oncology	2014	674
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Martin Früh, Dirk De Ruysscher, Sanjay Popat, Annals of Oncology MedicineCancer ManagementPulmonary BlastomaOncologyRadiation Oncology	2013	608
Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approach Johannes A. Langendijk, Philippe Lambin, Dirk De Ruysscher, Radiotherapy and Oncology Model-based ApproachPharmacotherapyParticle TherapyStepwise MethodologySide Effects	2013	521
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up Johan Vansteenkiste, Lucio Crinò, Christophe Dooms, Annals of Oncology Advanced Lung DiseaseMedicineCancer ManagementEsmo Consensus ConferencePulmonary Blastoma	2014	492
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Johan Vansteenkiste, Dirk De Ruysscher, Wilfried Eberhardt, Annals of Oncology Non-small-cell Lung CancerAdvanced Lung DiseaseMedicineCancer ManagementPulmonary Medicine	2013	487
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE) Wilfried Eberhardt, Christoph Pöttgen, Thomas Gauler, Journal of Clinical Oncology	2015	353
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer K.M. Kerr, L. Bubendorf, Martin J. Edelman, Annals of Oncology Molecular BiomarkersPrognostic BiomarkersOncologyNon-small-cell Lung CancerMedicine	2014	286
Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis Abhishek D. Garg, Dirk De Ruysscher, Patrizia Agostinis OncoImmunology Metagene SignaturesImproved SurvivalImmunologyPathologyTumor Biology	2015	248
The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer Wouter van Elmpt, Dirk De Ruysscher, Anke van der Salm, Radiotherapy and Oncology MedicineBronchial NeoplasmCancer TreatmentOncologyRadiation Oncology	2012	227
How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons Andrea Peeters, Janneke P.C. Grutters, Madelon Pijls-Johannesma, Radiotherapy and Oncology Radiation MedicineRadiation TherapyTreatment VerificationParticle TherapyCost Analysis	2010	222

Page 1